The Search for Single-Domain Antibodies Interacting with the Receptor-Binding Domain of SARS-CoV-2 Surface Protein.


Journal

Bulletin of experimental biology and medicine
ISSN: 1573-8221
Titre abrégé: Bull Exp Biol Med
Pays: United States
ID NLM: 0372557

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 08 11 2022
medline: 28 7 2023
pubmed: 19 7 2023
entrez: 18 7 2023
Statut: ppublish

Résumé

We performed a search for nanoantibodies that specifically interact with the receptor-binding domain (RBD) of the SARS-CoV-2 surface protein. The specificity of single-domain antibodies from the blood sera of a llama immunized with RBD of SARS-CoV-2 surface protein S (variant B.1.1.7 (Alpha)) was analyzed by ELISA. Recombinant trimers of the SARS-CoV-2 spike protein were used as antigens. In this work, a set of single-domain antibodies was obtained that specifically bind to the RBD of the SARS-CoV-2 virus.

Identifiants

pubmed: 37464199
doi: 10.1007/s10517-023-05839-6
pii: 10.1007/s10517-023-05839-6
doi:

Substances chimiques

spike protein, SARS-CoV-2 0
Single-Domain Antibodies 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Membrane Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

225-228

Informations de copyright

© 2023. Springer Science+Business Media, LLC, part of Springer Nature.

Références

Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J. Immunol. Methods. 2007;324(1-2):13-25. https://doi.org/10.1016/j.jim.2007.04.008
doi: 10.1016/j.jim.2007.04.008 pubmed: 17568607 pmcid: 2014515
Gorchakov AA, Kulemzin SV, Guselnikov SV, Baranov KO, Belovezhets TN, Mechetina LV, Volkova OY, Najakshin AM, Chikaev NA, Chikaev AN, Solodkov PP, Larichev VF, Gulyaeva MA, Markhaev AG, Kononova YV, Alekseyev AY, Shestopalov AM, Yusubalieva GM, Klypa TV, Ivanov AV, Valuev-Elliston VT, Baklaushev VP, Taranin AV. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. Cell Discov. 2021;7(1):96. https://doi.org/10.1038/s41421-021-00340-8
doi: 10.1038/s41421-021-00340-8 pubmed: 34667147 pmcid: 8526700
Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr. Opin. Investig Drugs. 2009;10(11):1212-1224.
pubmed: 19876789
Esmagambetov IB, Shcheblyakov DV, Egorova DA, Voronina OL, Derkaev AA, Voronina DV, Popova OA, Ryabova EI, Shcherbinin DN, Aksenova EI, Semenov AN, Kunda MS, Ryzhova NN, Zubkova OV, Tukhvatulin AI, Logunov DYu, Naroditsky BS, Borisevich SV, Gintsburg AL. Nanobodies are potential therapeutic agents for the Ebola virus infection. Acta Naturae. 2021;13(4):53-63. https://doi.org/10.32607/actanaturae.11487
Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob. Agents Chemother. 2015;60(1):6-13. https://doi.org/10.1128/AAC.01802-15
doi: 10.1128/AAC.01802-15 pubmed: 26438495 pmcid: 4704182
Lu Q, Zhang Z, Li H, Zhong K, Zhao Q, Wang Z, Wu Z, Yang D, Sun S, Yang N, Zheng M, Chen Q, Long C, Guo W, Yang H, Nie C, Tong A. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. J. Nanobiotechnology. 2021;19(1):33. https://doi.org/10.1186/s12951-021-00768-w
doi: 10.1186/s12951-021-00768-w pubmed: 33514385 pmcid: 7844813
Zebardast A, Hosseini P, Hasanzadeh A, Latifi T. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. Mol. Biol. Rep. 2022;49(1):647-656. https://doi.org/10.1007/s11033-021-06819-7
doi: 10.1007/s11033-021-06819-7 pubmed: 34648139
Tikunova NV, Morozova VV. Phage display on the base of filamentous bacteriophages: application for recombinant antibodies selection. Acta Naturae. 2009;1(3):20-28.
doi: 10.32607/20758251-2009-1-3-20-28 pubmed: 22649612 pmcid: 3347532
Vyatchanin AS, Tillib SV. Modifications in the phage display procedure to increase selection efficiency of antigen-binding domains on distinguished single-chain camel antibodies. Biotech. Russ. 2008;(4):30-38.
Brissette R, Goldstein NI. The use of phage display peptide libraries for basic and translational research. Methods Mol. Biol. 2007;383:203-213. https://doi.org/10.1007/978-1-59745-335-6_13
doi: 10.1007/978-1-59745-335-6_13 pubmed: 18217687
Pardon E, Laeremans T, Triest S, Rasmussen SG, Wohlkönig A, Ruf A, Muyldermans S, Hol WG, Kobilka BK, Steyaert J. A general protocol for the generation of Nanobodies for structural biology. Nat. Protoc. 2014;9(3):674-693. https://doi.org/10.1038/nprot.2014.039
doi: 10.1038/nprot.2014.039 pubmed: 24577359 pmcid: 4297639
World Health Organization (WHO). Coronavirus disease (COVID-19). URL: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019

Auteurs

V S Aripov (VS)

State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia. aripov_vs@vector.nsc.ru.

N V Volkova (NV)

State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

A V Taranin (AV)

Institute of Molecular and Cellular Biology, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.

L V Mechetina (LV)

Institute of Molecular and Cellular Biology, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.

N A Chikaev (NA)

Institute of Molecular and Cellular Biology, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.

A M Nayakshin (AM)

Institute of Molecular and Cellular Biology, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.

V S Nesmeyanova (VS)

State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

A A Isaeva (AA)

State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

Yu A Merkul'eva (YA)

State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

D V Shanshin (DV)

State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

S V Belenkaya (SV)

State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

A A Ilyichev (AA)

State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

D N Shcherbakov (DN)

State Research Center of Virology and Biotechnology "VECTOR", Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Koltsovo, Novosibirsk region, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH